• プロフィール
• 研究活動
• 著書・論文
• 社会・地域活動
• 教育活動
• その他

プロフィール

研究活動

著書・論文

【論文】
1）Iwamura H, Murakami S, Koshimizu K, Matsubara S, Quantitative analysis of anticytokinin activity 　　　　of 4-substituted-2-methylthiopyrido[2,3-d]pyrimidines. Phytochemistry 18, 1265-1268 (1979).　
2）Matsukura H, Murakami S, Sato M, The defensive mechanism of CL-1700 on gastric mucosa. Jpn J Pharmacol 32, 229P (1982).
3）Murakami S, Mori Y, Changes in the incorporating activity of 35S-sulfate into gastric sulfated glycoproteins in the rats with erosions by restraint and water immersion stress. Jpn J Pharmacol 35, 279-286 (1984).
4）Fujimoto N, Murakami S, Suwa T, Mori Y, The studies on the role of gastric glycoproteins with reference to cytoprotection. J Pharmacobio-Dyn 7, 864-871 (1984).
5）Iwamura H, Murakami S, Koshimizu K, Matsubara S, Quantitative structure-activity relationships in cytokinin agonistic and antagonistic pyrido[2,3-d]pyrimidine derivatives: Insight into receptor topology. J Med Chem 28, 577-583 (1985).
6）Murakami S, Mori Y, Effect of water immersion stress on the biosynthesis of rat gastric glycoproteins with or without sulfate. J Pharmacobio-Dyn 8, 235-245 (1985).
7）石倉美治、村上 茂、森 陽、ラット酢酸潰瘍の治癒過程における胃糖タンパク質生合成活性の変動. 日本薬理学雑誌 85 327-333 (1985).
8）Murakami S, Fujimoto N, Mori Y, Prostaglandin cytoprotection linked to the adhesion of mucous glycoprotein to the gastric epithelium. J Pharmacobio-Dyn 9, 359-367 (1986).
9）Murakami S, Mori Y, Changes in the structure of rat mucous glycoprotein and prostaglandin cytoprotection. J Pharmacobio-Dyn 9, 760-770 (1986).
10）Murakami S, Muramatsu M, Aihara H, Effect of sofalcone on gastric prostaglandin metabolism in taurocholate induced gastritis in rats. Res Commun Chem Pathol Pharmacol 53, 289-300 (1986).
11）仲西城太郎、村上 茂、諏訪俊男、岸本真也、森 陽、Taurocholic acid惹起胃炎における金属protease産生抑制作用. 応用薬理 32, 1113-1117 (1986).
12）Muramatsu M, Murakami S, Arai I, Isobe Y, Hirose H, Usuki C, Aihara H, Effect of sofalcone on acute gastric mucosal lesions induced by aspirin and ethanol in reference to the biosynthesis of gastric mucosal glycoprotein. Res Commun Chem Pathol Pharmacol 54, 321-337 (1986).
13）村上 茂、藤本 昇、森 陽、胃粘液糖タンパク質とcytoprotection. 実験潰瘍 13, 183 (1986).
14）仲西城太郎、村上 茂、石倉美治、森 陽、実験慢性潰瘍時における金属プロテアーゼの動態. 実験潰瘍 13, 183 (1986).　
15）Nakanishi J, Murakami S, Ishikura Y, Tsuchiya S, Mori Y, Production of metalloproteinase in gastric tissue with acetic acid induced gastritis. J Pharmacobio-Dyn 10, 92-97 (1987).
16）Muramatsu M, Tanaka M, Murakami S, Aihara H, Inhibition of 15-hydroxy- prostaglandin dehydrogenase and increase of prostaglandin E2. Life Sci 41, 315-322 (1987).
17）Murakami S, Muramatsu M, Aihara H, Honda A, Mori A, Enzymatic sulfation of gastric mucous glucoprotein in rat. Res Commun Chem Pathol Pharmacol 57, 77-98 (1987).
18）Murakami S, Yamada H, Muramatsu M, Aihara H, Suwa T, Kishimoto S, Mori Y, Effect of sofalcone on gastric mucous glycoprotein in experimental gastritis induced by sodium taurocholate. Res Commun Chem Pathol Pharmacol 62, 461-482 (1988).
19）Murakami S, Kijima H, Isobe Y, Muramatsu M, Aihara H, Otomo S, Lian-niang L, Chun-bo A, Effect of salvianolic acid A, a depside from roots of salvia miltiorrhiza, on gastric H+,K+-ATPase. Planta Med 56, 360-363 (1990).
20）Murakami S, Kijima H, Isobe Y, Muramatsu M, Aihara H, Otomo S, Baba K, Kozawa M, Inhibition of gastric H+,K+-ATPase by chalcone derivatives, xanthoangerol and 4-hydroxyderricin, from Angelica keiskei koidzumi. J Pharm Pharmacol 42, 723-726 (1990).
21）Murakami S, Muramatsu M, Otomo S, Oleic acid as an inhibitor of gastric H+,K+-ATPase. Res Commun Chem Pathol Pharmacol 71, 337-350 (1991).
22）Murakami S, Isobe Y, Kijima H, Nagai H, Muramatsu M, Otomo S, Inhibition of gastric H+,K+-ATPase and acid secretion by ellagic acid. Planta Med 57, 305-308 (1991).
23）Ito A, Kakizaki M, Nagase H, Murakami S, Yamada H, Mori Y, Effects of H2-receptor antagonists on matrix metalloproteinases in rat gastric tissues with acetic acid-induced ulcer. J Pharmacobio- Dyn 14, 285-291 (1991).
24）Murakami S, Muramatsu M, Aihara H, Otomo S, Inhibition of gastric H+,K+- ATPase by the antiulcer agent, sofalcone. Biochem Pharmacol 42, 1447-1451 (1991).
25）Yamori Y, Murakami S, Nara Y, Activated acyl coenzyme A-cholesterol acyltransferase as a possible cause of rapid arterial fat deposition in genetic hypertensive rat models for atherosclerosis. J Vascular Med Biol 3, 268-270 (1991).
26）Murakami S, Muramatsu M, Otomo S, Inhibition of gastric H+,K+-ATPase by quercetin. J Enzyme Inhib 5, 293-298 (1992).
27）Murakami S, Muramatsu M, Otomo S, Gastric H+,K+-ATPase inhibition by catechins. J Pharm Pharmacol 44, 926-928 (1992).
28）Murakami S, Mutamatsu M, Otomo S, Inhibitory effect of tannic acid on gastric H+,K+-ATPase. J Nat Prod 55, 513-516 (1992).
29）Murakami S, Arai I, Muramatsu M, Otomo S, Baba K, Kido T, Kozawa M, Inhibition of gastric H+,K+-ATPase and acid secretion by Cassigarol A, a polyphenol from cassia garretiana craib. Biochem Pharmacol 44, 33-37 (1992).
30）Murakami S, Arai I, Muramatsu M, Otomo S, Baba K, Kozawa M, Daphnodorins inhibit gastric H+,K+-ATPase and acid secretion. Pharmaceut Pharmacol Lett 2, 108-112 (1992).
31）Murakami S, Arai I, Muramatsu M, Otomo S, Baba K, Kido T, Kozawa M, Effect of stilbene derivatives on gastric H+,K+-ATPase. Biochem Pharmacol 44, 1947-1951 (1992).
32）Yamori Y, Nara Y, Mizushima S, Murakami S, Ikeda K, Sawamura M, Nabika T, Horie R, Gene-environment interaction in hypertension, stroke and atherosclerosis in experimental models and supportive findings from a world-wide cross-sectional epidemiological survey: a WHO-cardiac study. Clin Exp Pharmacol Physiol 20 (Suppl), 45-52 (1992).
33）Murakami S, Muramatsu M, Otomo S, Structure-activity relationships of unsaturated long chain fatty acids in relation to the inhibition of gastric H+,K+-ATPase. Res Commun Mol Pathol Pharmacol 85, 57-66 (1994).
34）Murakami S, Ohta Y, Asami Y, Yamagishi I, Toda Y, Araki H, Otomo S, Hypolipidemic effects of HL-004, a novel ACAT inhibitor, in hamsters fed normal chow. Atherosclerosis 109, 311 (1994).
35）Yanagita T, Sonda K, Yotsumoto H, Yamamoto K, Murakami S, Effects of ACAT inhibitors HL-004 and CI-976 on the synthesis and secretion of esterified cholesterol and on the de novo synthesis of cholesterol and glycolipids in HepG2 cells. Atherosclerosis 109, 311 (1994).
36）Murakami S, Araki H, Otomo S, Nara Y, Yamori Y, Effects of HL-004, a novel ACAT inhibitor, on cholesterol accumulation and removal in cultured smooth muscle cells from stroke-prone spontaneously hypertensive rats (SHRSP). Life Sci 56, 509-520 (1995).
37) Murakami S, Nara Y, Yamori Y, Peritoneal macrophages from stroke-prone spontaneously hypertensive rats accumulate more cholesteryl ester than do macrophages from Wistar-Kyoto rats. Biochem Biophys Res Commun 211, 547-553 (1995).
38）Yanagita T, Sonda K, Yamamoto K, Yotsumoto H, Nunez JH, Murakami S, Effect of a new acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor HL-004 on cholesterol esterification and lipid metabolism in HepG2 cells. Curr Ther Res 56, 787-795 (1995).
39）Yamori Y, Murakami S, Nara Y, Ikeda K, Stroke-prone SHR and atherosclerosis-prone SHR as models for atherosclerosis: Their mechanisms and application for nutritional and pharmacological studies. Clin Exp Pharmacol Physiol S244-S245 (1995).
40）Murakami S, Yamagishi I, Ohta Y, Toda Y, Nara Y, Yamori Y, Hypolipidemic effect of taurine in stroke-prone spontaneously hypertensive rats (SHRSP). Pharmacology 42, 303-313 (1996).
41）Murakami S, Nara Y, Yamori Y, Taurine accelerates the regression of hypercholesterolemia in stroke-prone spontaneously hypertensive rats (SHRSP). Life Sci 58, 1643-1651 (1996).
42）Asami Y, Ohta Y, Yamagishi I, Murakami S, Araki H, Higuchi S, Effects of a novel ACAT inhibitor HL-004 on cholesterol absorption in cholesterol-fed models. Jpn J Pharmacol 71, 149P (1996).
43）Yamagishi I, Murakami S, Asami Y, Araki H, Higuchi S, Effect of the ACAT inhibitor HL-004 on cholesterol metabolism in macrophages. Jpn J Pharmacol 71, 149P (1996).
44）Murakami S, Nara Y, Yamori Y, Hypolipidemic and anthatherosclerotic effects of a novel ACAT inhibitor, HL-004, in stroke-prone spontaneously hypertensive rats. Exp Mol Pathol 63, 23-32 (1995).
45）Murakami S, Ohta Y, Asami Y, Yamagishi I, Sato M, Tomisawa K, The hypolipidemic action of the ACAT inhibitor HL-004 in hamsters fed normal chow. Gen Pharmacol 27, 1383-1386 (1996).
46）Murakami S, Yamagishi I, Asami Y, Sato M, Tomisawa K, Effect of ACAT inhibitor, HL-004, on cholesterol metabolism in macrophages. Cell Mol Biol 42, 865-872 (1996).
47）Murakami S, Yamagishi I, Sato M, Tomisawa K, Nara Y, Yamori Y, ACAT inhibitor HL-004 accelerates the regression of hypercholesterolemia in stroke-prone spontaneously hypertensive rats (SHRSP): stimulation of bile acid production by HL-004. Atherosclerosis 133, 97-104 (1997).
48）Asami Y, Yamagishi I, Murakami S, Araki H, Tsuchida K, Higichi S, HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits. Life Sci 62, 1055-1063 (1998).
49）Asami Y, Kondo Y, Murakami S, Araki H, Tsuchida K, Higichi S, The ACAT inhibitor HL-004 inhibits cholesterol absorption and lowers serum cholesterol in rats. Gen Pharmacol 31, 593-596 (1998).
50）Ishii I, Yokoyama N, Yanagimachi M, Ashikawa N, Hata M, Murakami S, Asami Y, Morisaki N, Saito Y, Ohmori S, Kitada M, Stimulation of cholesterol relase from rabbit foam cells by the action of a new inhibitor for acyl CoA:cholesterol acyltransferase (ACAT), HL-004. J Pharmacol Exp Ther 287, 115-121 (1998).
51）Murakami S, Muramatsu M, Tomisawa K, Inhibition of gastric H+,K+-ATPase by flavonoids: a structure-activity study. J Enzyme Inhib 14, 151-121 (1999).
52）Murakami S, Kondo-Ohta Y, Tomisawa K, Improvement of cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet. Life Sci 64, 83-91 (1999).
53）Murakami S, Kondo Y, Tomisawa K, Nagate T, Taurine improves serum cholesterol levels and retards the progression of atherosclerosis. Atherosclerosis 144, Suppl 1, 68 (1999).
54）Murakami S, Nitanai I, Uchida S, Kondo-Ohta Y, Asami Y, Kondo K, Sato M, Hara H, Tomisawa K, Mei HB, Xiang CZ, Up-regulation of low density lipoprotein (LDL) receptor by a novel isobenzofranone derivative, MD-700. Atherosclerosis 146, 281-290 (1999).
55）Murakami S, Kondo Y, Nagate T, Prevention of atherosclerotic lesion development in mice by taurine. Drugs Exptl Clin Res 15, 227-234 (1999).
56）Yamamoto K, Yoshitama A, Sakono M, Nasu T, Murakami S, Fukuda N, Dietary taurine decreases hepatic secretion of cholesterol ester in rats fed a high-cholesterol diet. Pharmacology 60, 27-33 (2000).
57）Murakami S, Toda Y, Seki T, Munetomo E, Kondo Y, Sakurai T, Ohtsuka Y, Matsuyama M, Nagate T, Hosokawa N, Nagata K, Heat shock protein (HSP) 47 and collagen are up-regulated during neointimal formation in the balloon-injured rat carotid artery. Atherosclerosis 157, 361-368 (2001).
58）Chino Y, Minagawa T, Kohno Y, Toda Y, Murakami S, Higuchi S, Uptake by vascular smooth muscle cells plays an important role in targeting of lipid microspheres incorporating prostaglandin E1 into a thickened intima. Life Sci 68, 933-942 (2001).
59）Kondo Y, Toda Y, Kitajima H, Oda H, Nagate T, Kameo K, Murakami S, Taurine inhibits the development of atherosclerotic lesions in apolipoprotein E-deficient mice. Clin Exp Pharmacol Physiol 28, 809-815 (2001).
60）Murakami S, Kondo Y, Toda Y, Kitajima H, Nagate T, Kameo K, Sakono M, Fukuda N, Effect of taurine on cholesterol metabolism in hamsters: Up-regulation of low density lipoprotein (LDL) receptor by taurine. Life Sci 70, 2355-2366 (2002).　
61）Murakami S, Kondo Y, Kitajima H, Nagate T, Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis 163, 79-87 (2002).
62）Watarai M, Makino S, Michikawa M, Yanagisawa K, Murakami S, Shirahata T, Macrophage plasma membrane cholesterol contributes to Brucella abortus infection of mice. Infect Immun 70, 4818-4825 (2002).
63）梶田純代, 村上茂, 中池司郎, 磯部好彦, 木島春子, ラットモノクロラミン胃粘膜傷害に対するsofalconeの作用. 薬理と治療 30, 597-601 (2002).
64）Matsushima Y, Sekine T, Kondo Y, Sakurai T, Kameo K, Tachibana M, Murakami S, Effects of taurine on serum lipoproteins and development of atherosclerosis in spontaneously hyperlipidemic (SHL) mice. Clin Exp Pharmacol Physiol 30, 295-299 (2003).
65）Yoshimura H, Sugawara K, Saito M, Saito S, Murakami S, Miyata N, Kawashima A, Morimoto S, Gao N, Zhang X, Yang J, In vitro TGF-β antagonistic activity of ursolic and oleanolic acids isolated from Clerodendranthus spicatus. Planta Med 69, 673-675 (2003).
66）Terui Y, Yiwen C, Jun-ying L, Ando T, Yamamoto H, Kawamura Y, Tomishima Y, Uchida S, Okazaki T, Munetomo E, Seki T, Yamamoto K, Murakami S, Kawashima A, Xantholipin, a novel inhibitor of HSP47 gene expression produced by Streptomyces sp. Tetrahedron Lett 44, 5427-5430 (2003).
67）Yamori Y, Murakami S, Ikeda K, Nara Y, Fish and life-related disease prevention: experimental and epidemiological evidence for anti-atherogenic potential of taurine. Clin Exp Pharmacol Physiol 31, (Suppl 2) S20-S23 (2004).
68）Murakami S, Takashima H, Saitoh M, Sato-Watanabe M, Chonan S, Yamamoto K, Saito S, Yoshimura H, Sugawara K, Yang J, Gao N, Zhang X, Ursolic acid, an antagonist for TGF-β. FEBS Lett 566, 55-59 (2004).
69）Kato J, Ido A, Uto H, Hori T, Hayashi K, Murakami S, Terano A, Tsubouchi H, Tranforming growth factor-β-induced stimulation of collagen fiber network and anti-fibrotic effect of taurine in an in vitro model of hepatic fibrosis. Hepatol Res 30, 34-41 (2004).
70）Yanagita T, Han SY, Hu Y, Nagao K, Kitajima H, Murakami S, Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids Health Dis 7, 38-43 (2008).
71）Takahashi N, Kang MS, Kuroyanagi K, Goto T, Hirai S, Ohyama K, Lee JY, Yu R, Yano M, Sasaki T, Murakami S, Kawada T, Auraptene, a citrus fruit compound, regulates gene expression as a PPARγ agonist in HepG2 hepatocytes. Biofactors 33, 25-32 (2008).
72）Ando C, Takahashi N, Hirai S, Nishimura K, Lin S, Uemura T, Goto T, Yu R, Nakagami J, Murakami S, Kawada T, Luteolin, a food-derived flavonoid, suppresses adipocyte-dependent activation of macrophages by inhibiting JNK activation. FEBS Lett 583, 3649-3654 (2009).
73）Murakami S, Sakurai T, Tomoike H, Sakono M, Nasu T, Fukuda N, Prevention of hypercholesterolemia and atherosclerosis in the hyperlipidemia- and atherosclerosis-prone Japanese (LAP) quail by taurine supplementation. Amino Acids 38, 271-278 (2009).
74）Nagao K, Yamano N, Shirouchi B, Inoue N, Murakami S, Sasaki T, Yanagita T, Effect of citrus auraptene (7-geranyloxycoumarine) on hepatic lipid metabolism in vitro and in vivo. J Agric Food Chem 58, 9028-9032 (2010).
75）Murakami S, Sakurai T, Toda Y, Morito A, Sakono M, Fukuda N, Prevention of neointima formation by taurine ingestion after carotid balloon injury. Vascul Pharmacol 53, 177-184 (2010).
76) Fukuda N, Yoshitama A, Sugita S, Fujita M, Murakami S. Taurine reduces hepatic secretion of cholesteryl ester and enhances fatty acid oxidation in rats fed a high-cholesterol diet. J Nutr Sci Vitaminol 57, 144-149 (2011).
77) Goto T, Nagai H, Egawa K, Kim Y-Il, Kato S, Taimatsu A, Sakamoto T, Ebisu S,
Hosaka T, Miyagawa H, Murakami S, Takahashi N, Kawada T, Farnesyl
pyrophosphate regulates adipocyte function as an endogenous PPARγ
agonist. Biochem J 438, 111-119 (2011).
78) Takahashi N, Senda M, Lin S, Goto T, Yano M, Sasaki T, Murakami S, Kawada
T. Auraptene regulates gene expression involved in lipid metabolism through PPARγ activation in diabetic obese mice.Mol Nutr Food Res 55, 1791-1797 (2011).
79) Lin S, Hirai S, Yamaguchi Y, Goto T, Takahashi N, Tani F, Mutoh C, Sakurai T, Murakami S, Yu R, Kawada T, Taurine improves obesity-induced inflammatory responses and modulates the unbalanced phenotype of adipose tissue macrophages. Mol Nutr Food Res 57, 2155-2165 (2013).
80) Abe Y, Ohkuri T, Yoshitomi S, Murakami S, Ueda T, Role of osmolyte taurine on the folding of a model protein, hen egg white lysozyme, under a crowded condition. Amino Acids 47, 909-915 (2015).
81) Sagara M, Murakami S, Mizushima S, Liu L, Mori M, Ikeda K, Nara Y, Yamori Y, Taurine in 24-hour urine is inversely related to cardiovascular risks in middle aged subjects of 50 populations in the world. Adv Exp Med Biol 803, 623-636 (2015).
82) 高橋正和、村上茂、久保義人、小林恭一　福井県産ウメ抽出物ならびにエゴマ油成分の肝細胞脂肪蓄積抑制作用の検討、福井県立大学論集 45, 47-55 (2015).
83) Murakami S, Fujita M, Nakamura M, Sakono M, Nishizono S, Sato M, Imaizumi K, Fukuda N, Taurine ameliorates cholesterol metabolism by stimulating bile acid production in high-cholesterol-fed rats. Clin Exp Pharmacol Physiol 43, 372-8 (2016).
84) Li Y, Goto T, Yamakuni K, Takahashi H, Takahashi N, Jheng HF, Nomura W, Taniguchi M, Baba K, Murakami S, Kawada T, 4-Hydroxyderricin, as a PPARγ agonist, promotes adipogenesis, adiponectin secretion, and glucose uptake in 3T3-L1 cells. Lipids 51, 787-95 (2016).
85) Li Y, Goto T, Ikutani R, Lin S, Takahashi N, Takahashi H, Jheng HF, Yu R, Taniguchi M, Baba K, Murakami S, Kawada T, Xanthoangelol and 4-hydroxyderrcin suppress obesity-induced inflammatory responses. Obesity (Silver Spring) 24, 2351-2360 (2016).
86)Iwase M, Yamamoto T, Nishimura K, Takahashi H, Mohri S, Li Y, Jheng HF, Nomura W, Takahashi N, Kim CS, Yu R, Taniguchi M, Baba K, Murakami S, Kawada T, Goto T, Suksdorfin Promotes Adipocyte Differentiation and Improves Abnormalities in Glucose Metabolism via PPARγ Activation. Lipids 52, 657-664 (2017).
87) Kawabata K, Kitamura K, Irie K, Naruse S, Matsuura T, Uemae T, Taira S,
Ohigashi H, Murakami S, Takahashi M, Kaido Y, Kawakami B, Triterpenoids isolated from Ziziphus jujuba enhance glucose uptake activity in skeletal muscle cells. J Nutr Sci Vitaminol 63, 193-199 (2017).
88) Kawasaki A, Ono A, Mizuta S, Kamiya M, Takenaga T, Murakami S, The taurine
content of Japanese seaweed. Adv Exp Med Biol 975, 1105-1112 (2017).
89) Kawabata K, Baba N, Sakano T, Hamano Y, Taira S, Tamura A, Baba S, Natsume M, Ishii T, Murakami S, Ohigashi H, Functional properties of anti-inflammatory substances from quercetin-treated Bifidobacterium adolescentis. Biosci Biotechnol Biochem 82, 689-697 (2018).
90) Ito T, Okazaki K, Nakajima D, Shibata D, Murakami S, Schaffer S, Mass spectrometry-based metabolomics to identify taurine-modified metabolites in heart. Amino Acids 50, 117-124 (2018).
91) Ito T, Nakanishi Y, Yamaji N, Murakami S, Schaffer SW, Induction of growth
differentiation factor 15 in skeletal muscle of old taurine transporter knockout mouse. Biol Pharm Bull 41, 435-439 (2018).
92) Murakami S, Ono A, Kawasaki A, Takenaga T, Ito T, Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. Amino Acids 50, 1279-1288 (2018).
87) Ito T, Hanahata Y, Kine K, Murakami S, Schaffer SW, Tissue taurine depletion induces profibrotic pattern of gene expression and causes aging-related cardiac fibrosis in heart in mice. Biol Pharm Bull 41, 1561-1566 (2018).
88) Ito T, Murakami S, Schaffer SW, Taurine-conjugated metabolites in hearts. Adv Exp Med Biol 1155, 523-529 (2019).
89) Nguyen KH, Ito S, Maeyama S, Schaffer SW, Murakami S, Ito T, In vivo and in vitro study of N-methyltaurine on pharmacokinetics and antimuscle atrophic effects in mice. ACS Omega 5, 11241-11246 (2020).
90) Murakami S*, Hirazawa C, Ohya T, Yoshikawa R, Mizutani T, Ma N, Moriyama M, Ito T, Matsuzaki C. The edible brown seaweed Sargassum horneri (Turner) C. Agardh ameliorates high-fat diet-induced obesity, diabetes, and hepatic steatosis in mice. Nutrients 13, 551 (2021).
91) Kamiya Y, Odama M, Mizuguti A, Murakami S, Ito T. Puerarin blocks the aging phenotype in human dermal fibroblasts. PLoS One 16, e0249367 (2021).
92) Tsubotani K, Maeyama S, Murakami S, Schaffer SW, Ito T. Taurine suppresses liquid-liquid phase separation of lysozyme protein. Amino Acids 53, 745-751 (2021).
93) Yoshimura T, Inokuchi Y, Mutou C, Sakurai T, Nagahama T, Murakami S*
Age-related decline in the taurine content of the skin in rodents. Amino Acids 53, 429-434 (2021).
94) Yoshimura T, Manabe C, Inokuchi Y, Mutou C, Nagahama T, Murakami S*. Protective effect of taurine on UVB-induced skin aging in hairless mice. Biomed Pharmacother 141, 111898 (2021).
95) Murakami S, Hirazawa C, Yoshikawa R, Mizutani T, Ohya T, Ma N, Ikemori T, Ito T, Matsuzaki C, Edible red seaweed Campylaephora hypnaeoides J. Agardh alleviates obesity and related metabolic disorders in mice by suppressing oxidative stress and inflammatory response. Metab Nutr (Lond) 19, 4 (2022).
96) Murakami S, Hirazawa C, Mizutani T, Yoshikawa R, Ohya T, Ma N, Owaki Y, Owaki T, Ito T, Matsuzaki C. The anti-obesity and anti-diabetic effects of the edible seaweed Gloiopeltis furcata (Postels et Ruprecht) J. Agardh in mice fed a high-fat diet. Food Sci Nutr 11, 599-610 (2022).
97) Khanh Hoang N, Maegawa E, Murakami S, Schaffer SW, Ito T. N-Chlorotaurine reduces the lung and systemic inflammation in LPS-induced pneumonia in high fat diet-induced obese mice. Metabolites 12, 349 (2022).
98) Murakami S, Funahashi K, Tamagawa N, Ning M, Ito T. Taurine ameliorates streptozotocin-induced diabetes by modulating hepatic glucose metabolism and oxidative stress in mice. Metabolites 12, 524 (2022).
99) Satsu H, Gondo Y, Shimanaka H, Imae M, Murakami S, Watari K, Wakabayashi S, Park SJ, Nakai K, Shimizu M. Signaling pathway of taurine-induced upregulation of TXNIP. Metabolites 12, 636 (2022).
100) Nguyen KH, Murakami S, Schaffer SW, Ito T. Examination of taurine chloramine and taurine on LPS-induced acute pulmonary inflammatory in mice. Adv Exp Med Biol 1370, 23-29 (2022).
101) Ito T, Nguyen KH, Maruyama C, Hamano Y, Murakami S, Schaffer SW. Bioavailability of tauropine after oral ingestion in mouse. Adv Exp Med Biol 1370, 137-142 (2022).
102) Yoshimura T, Manabe C, Nagumo J, Nagahama T, Sato T, Murakami S. Taurine accelerates the synthesis of ceramides and hyaluronic acid in cultured epidermis and dermal fibroblasts. Exp Ther Med in press
103) Odama M, Maegawa E, Suzuki K, Fujii Y, Maeda R, Murakami S, Ito T. J Agric Food Chem. Effects of Betulinic Acid on the Proliferation, Cellular Senescence, and Type 1 Interferon-Related Signaling Pathways in Human Dermal Fibroblasts. 2023 May 10;71(18):6935-6943.
【総説】 1) 村上茂 脳卒中易発症高血圧ラット（SHRSP）におけるタウリンの脂質低下改善作用、日本農芸化学会誌　第75巻　9号　972-975 (2001).
2) Yamori Y, Liu L, Mori M, Sagara M, Murakami S, Nara Y, Mizushima S, Taurine as the nutritional factor for the longevity of the Japanese revealed by a world-wide epidemiological survey. Adv Exp Med Biol 643, 13-25 (2009).
3) Murakami S Taurine and atherosclerosis. Amino Acids 46, 73-80 (2014)
4) Imae M, Asano T, Murakami S Potential role of taurine in the prevention of diabetes and metabolic syndrome. Amino Acids 46, 81-88 (2014)
5) Murakami S The role of taurine in the pathogenesis of obesity. Mol Nutr Food Res 59, 1353-1363 (2015).
6) Murakami S The physiological and pathophysiological roles of taurine in adipose tissue in relation to obesity. Life Sci 186, 80-86 (2017).

【著書】
1) Murakami S, Suwa T, Mori Y, Gastric mucosal glycoprotein and the effects of
sofalcone. In New trends in peptic ulcer and chronic hepatitis- Part. 1 Excepta Medica, 341 (1985).
2) Murakami S, Yamashita M, Nara Y, Yamori Y, Taurine improves cholesterol metabolism in stroke-prone spontaneously hypertensive rats (SHRSP) fed on hypercholesterolemic (HC) diets. In Genetic hypertension, John Libbey Eurotex Ltd., 397 (1992).
3) Murakami S, Kondo Y, Nagate T, Effects of long-term treatment with taurine in mice fed a high-fat diet. In Taurine 4- Taurine and excitable tissues-, Kluwer Academic/Plenum Publishers, New York, 177-186 (2000).
4) Kondo Y, Murakami S, Oda H, Nagate T, Taurine reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. . In Taurine 4- Taurine and excitable tissues-, Kluwer Academic/Plenum Publishers, New York, 193-202 (2000).
5) Murakami S, Yamori Y, Taurine and longevity- Preventive effect of taurine on metabolic syndrome. In Bioactive food as dietary interventions for the aging population. Edited by Watson RR and Preedy VR, Academic Press/Elsevier, San Diego USA (2012)
6) 高橋正和、村上茂、片野肇、村上亜由美、小林恭一、橋本直哉、天谷美都希、久保義人、福井県産農作物の機能性解析と機能性成分の効率的精製法　食品と開発、50巻、11号、73-76 2015年
7) 村上茂　監修・著、読んで効くタウリンのはなし、成山堂、2016年
8) 村上茂　北陸路に棗ありて、薬理作用総論p67-85 金森昌彦 編集 三恵社、2017年
9) 村上茂　エゴノリの健康効果の解明と機能性食品としての開発の可能性、テクノふくい、98巻, 38-41，2018年
10) 村上茂　生体におけるタウリンの役割、食品分析開発センター SUNATECメールマガジン　2019年7月号
11) 村上茂，健康維持における食の重要性，健康生活科学（福井県立大学大学院看護福祉学研究科 編），福井県立大学ブックレット12-21 (2021)
12) 村上茂　海藻で福井を元気に！　掘り起こそう！生活に身近な生物資源学 いまとこれから，（福井県立大学生物資源学部生物資源学科 編），福井県立大学ブックレット98-103 (2022)
13) 高橋正和、村上茂　食べ物の機能性―栄養・おいしさ・生理機能―　掘り起こそう！生活に身近な生物資源学 いまとこれから，（福井県立大学生物資源学部生物資源学科 編），福井県立大学ブックレット10-14 (2022)

社会・地域活動

NPO法人世界健康フロンティア研究会 理事　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　国際タウリン研究会日本部会 理事長

教育活動

その他

佐賀大学客員教授 （2003年度）